Remicade Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Remicade market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the prevalence of autoimmune diseases, greater acceptance and use of biologic therapies, advancements in healthcare infrastructure, patent exclusivity periods, and clinical effectiveness.

The projected growth in the forecast period is driven by the increasing presence of biosimilars, the global disease burden, market expansion in emerging economies, regulatory and insurance support, and rising disposable income. Key trends during this period include the adoption of biosimilars, integration of digital health solutions, personalized medicine, innovations in biologic therapies, and improvements in drug delivery systems.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the remicade market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own cells, tissues, or organs, mistaking them for foreign invaders. The rise in autoimmune diseases is attributed to a combination of genetic factors, environmental changes, greater exposure to pollutants, lifestyle choices, and improved diagnostic capabilities. Remicade (infliximab) is used to treat autoimmune conditions by targeting and inhibiting tumor necrosis factor-alpha (TNF-α), a critical inflammatory cytokine involved in diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. For example, the Centers for Disease Control and Prevention (CDC) reported in February 2024 that in 2022, 18.9% of adults aged 18 and older were diagnosed with arthritis, with a higher prevalence among women (21.5%) than men (16.1%). The prevalence also increased with age, ranging from 3.6% in individuals aged 18-34 to 53.9% in those aged 75 and above. This rising incidence of autoimmune diseases is expected to boost the growth of the remicade market.

A notable trend in the remicade market is the increasing focus on innovation in drug formulation, particularly with the development of subcutaneous versions of medications. These formulations offer improved patient convenience, better treatment adherence, and greater market accessibility, as they provide a quicker and easier alternative to traditional intravenous treatments. For example, in March 2024, Celltrion USA, Inc. launched Zymfentra, the first subcutaneous formulation of infliximab approved by the FDA. Zymfentra (infliximab-dyyb) is indicated for the maintenance therapy of adults with moderate-to-severe active ulcerative colitis (UC) and Crohn's disease (CD), both of which are forms of inflammatory bowel disease (IBD). The approval allows it to be used after prior treatment with an intravenous infliximab product, providing a more convenient option for long-term disease management.

In September 2024, Tharimmune Inc., a U.S.-based biopharmaceutical company, acquired a global license from Intract Pharma to develop an oral version of infliximab, which has traditionally been administered intravenously. This new oral formulation aims to improve patient compliance and potentially lower healthcare costs related to long-term intravenous treatments. Intract Pharma Ltd., based in the UK, specializes in the development of infliximab-based treatments.

The key company operating in the remicade market is Janssen Biotech Inc.

North America was the largest region in the remicade market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in remicade report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the remicade market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Remicade (infliximab) is a biologic medication classified as a tumor necrosis factor-alpha (TNF-α) inhibitor. It is used to treat autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By inhibiting TNF-α, a protein involved in inflammation, Remicade helps alleviate symptoms, slow disease progression, and improve quality of life.

The primary disease indications for remicade include Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis. Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract, often causing symptoms such as abdominal pain, severe diarrhea, weight loss, and fatigue. Remicade can be administered through subcutaneous, intravenous, or parenteral routes, with the end users including hospitals, clinics, ambulatory care settings, and home care.

The remicade market research report is one of a series of new reports that provides remicade market statistics, including remicade industry global market size, regional shares, competitors with a remicade market share, detailed remicade market segments, market trends and opportunities, and any further data you may need to thrive in the remicade industry. This remicade market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade market consists of sales of biosimilars of remicade, combination therapy products, administration tools, and packaging formats. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.